Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20803561 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL22692383 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL22198634 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL21914949 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL21914903 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL24173258 | 1.00 | C3AR1 (0.34) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL23961958 | 0.96 | SIRT6 (0.35) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL24172987 | 0.92 | FURIN (0.33) | C3AR1FURINPOLBLMNAKMT2A | |
| SCHEMBL23105946 | 0.91 | C3AR1 (0.33) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL21503810 | 0.91 | C3AR1 (0.33) | C3AR1SIRT5SIRT6SIRT1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023201234-A2 | ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2023-10-19 | — | — | WO | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | MC SAF (FR) | 2023-09-07 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20190233531-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION | 2019-08-01 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10280229-B2 | Linkers and their application towards ADC | MEDSHINE DISCOVERY INC. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION | 2018-04-12 | — | — | US | disclosed |
| WO-2017132617-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132615-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170202974-A1 | LINKERS AND THEIR APPLICATION TOWARDS ADC | MEDSHINE DISCOVERY INC. (CN) | 2017-07-20 | — | — | US | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | SHBG, SERPINA6, F13B | C3AR1 134/4885FURIN 1484/4885POLB 3960/4885 |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | C3AR1 584/4885FURIN 1137/4885POLB 4116/4885 |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | C3AR1 419/4885FURIN 2386/4885POLB 4348/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | C3AR1 143/4885FURIN 4013/4885POLB 3279/4885 |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | C3AR1 565/4885FURIN 2795/4885POLB 3899/4885 |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | C3AR1 78/4885FURIN 417/4885POLB 3159/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | C3AR1 104/4885FURIN 3721/4885POLB 3714/4885 |
| US-20170202974-A1 | LINKERS AND THEIR APPLICATION TOWARDS ADC | DNPEP, DPP7, DPP3 | C3AR1 1547/4885FURIN 225/4885POLB 3097/4885 |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | C3AR1 217/4885FURIN 2107/4885POLB 1899/4885 |
| US-20190233531-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | SIGLEC9, SIGLEC7, STT3B | C3AR1 1874/4885FURIN 822/4885POLB 2056/4885 |
| US-10280229-B2 | Linkers and their application towards ADC | DNPEP, DPP7, DPP3 | C3AR1 1547/4885FURIN 225/4885POLB 3097/4885 |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD99, CD63 | C3AR1 122/4885FURIN 2077/4885POLB 2436/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | C3AR1 606/4885FURIN 934/4885POLB 3931/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | C3AR1 931/4885FURIN 2349/4885POLB 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.